Obesity drugmaker Kailera plans an IPO [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Obesity drugmaker Kailera Therapeutics plans to test investor appetites for another biotechnology initial public offering, according to a Friday securities filing If successful, the company, which has several experimental weight loss medicines in testing, could join a short list of newly public biotechs that have raised more than $1.7 billion in proceeds so far this year. Kailera's most advanced prospect, ribupatide, is a weekly GLP-1/GIP agonist in late-stage testing. So far, Kailera and its partner Hengrui Pharma have published data from a 48-week Phase 3 trial in China showing that ribupatide helped people with obesity, on average, lose 18% of their body weight. The drugmaker expects to publish data from an earlier study of an increased dose next year, and findings from its global Phase 3 study in 2028. Earlier in development are two obesity medicines in pill form, as well as a so-called “tri-agonist” shot that will enter human studies later this year. One of those drugs,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Weak Share Performance [Yahoo! Finance]Yahoo! Finance
- Mars CEO gets board role at GLP-1 supplier Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk (NVO) Shares Up Since Jim Cramer Said He Was A Buyer [Yahoo! Finance]Yahoo! Finance
- Stocks, sectors, and charts this strategist is watching [Yahoo! Finance]Yahoo! Finance
- 1 Reason This Biotech Stock Could Triple Before Year-End [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website